Influenza A virus vaccine H5N1 - Adimmune Corporation

Drug Profile

Influenza A virus vaccine H5N1 - Adimmune Corporation

Alternative Names: AdimFlu-W; Adjuvanted H5N1 influenza virus vaccine - Adimmune; Pandemic influenza virus vaccine H5N1 - Adimmune

Latest Information Update: 14 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adimmune Corporation
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Influenza A virus H5N1 subtype

Most Recent Events

  • 14 Dec 2015 Clinical development is ongoing in Taiwan
  • 01 Jul 2012 Phase-I/II clinical trials in Influenza-A virus H5N1 subtype (prevention) in Taiwan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top